🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. GM-CT-01 plus 5-Fluorouracil

    GALECTIN THERAPEUTICS INC

    Colorectal Cancer

    phase 2 small molecule terminated

    1 trial

  2. Gefitinib

    AstraZeneca

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  3. Gemcitabine

    Compass Therapeutics

    Metastatic Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  4. Gemcitabine

    HALOZYME THERAPEUTICS, INC.

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  5. Gemcitabine

    Regeneron UK Limited

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  6. Gemcitabine

    Chongqing Precision Biotech Co., Ltd

    Pancreatic Cancer, Adult

    phase 2 small molecule terminated

    1 trial

  7. Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, JNJ-42756493, Gemcitabine 2 g Powder for Solution for Infusion, JNJ-42756493, JNJ-42756493, Mitomycin medac 1 mg/ml Pulver zur Herstellung einer Injektions- bzw. Infusionslösung oder einer Lösung zur intravesikalen Anwendung

    Janssen-Cilag International N.V.

    Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions

    phase 2 small molecule active

    1 trial

  8. Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  9. Gemcitabine Oxaliplatin 5FU and Leucovorin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  10. Gemcitabine plus Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  11. Gemcitabine+simvastatin

    Samsung Bioepis NL B.V.

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  12. Gentuximab

    Changchun GeneScience Pharmaceutical Co.,

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  13. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  14. Giapreza 2.5 mg/ml concentrate for solution for infusion

    Disc Medicine

    Liver cancer (primary or secondary)

    phase 2 small molecule active

    1 trial

  15. Gilteritinib

    Astellas Pharma Inc

    Non-Small-Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  16. Gimistotug

    BEONE MEDICINES AUS PTY LTD

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  17. Giredestrant

    Hoffmann-La Roche

    Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  18. Giredestrant

    Hoffmann-La Roche

    Early Breast Cancer

    phase 2 small molecule completed

    1 trial

  19. GnP in combination with Ivonescimab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  20. Green tea

    United Therapeutics Europe Ltd

    Lung Cancer Prevention

    phase 2 other completed

    1 trial

  21. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    2 trials

  22. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  23. HRS-7058

    Shandong Suncadia Medicine Co.,

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  24. HYCAMTIN 4 mg powder for concentrate for solution for infusion, TAXOL 6 mg/ml, concentrato per soluzione per infusione., Neulasta 6 mg solution for injection, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion

    SUTRO BIOPHARMA, INC.

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources